Ligand Specificity in Fragment-Based Drug Design

被引:41
作者
Barelier, Sarah [1 ]
Pons, Julien [1 ]
Gehring, Kalle [2 ,3 ]
Lancelin, Jean-Marc [1 ]
Krimm, Isabelle [1 ]
机构
[1] Univ Lyon 1, Sci Analyt Lab, CNRS, ESCPE Lyon,UMR 5180, F-69100 Villeurbanne, France
[2] McGill Univ, Dept Biochem, Montreal, PQ H3G 0B1, Canada
[3] McGill Univ, Grp Rech Axe Struct Prot, Montreal, PQ H3G 0B1, Canada
关键词
BCL-2; FAMILY; POTENT INHIBITORS; LEAD GENERATION; NMR; DISCOVERY; BINDING; BCL-X(L); PROTEINS; PEROXIREDOXIN; AFFINITY;
D O I
10.1021/jm100496j
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Fragment-based drug design consists of identifying low-molecular weight compounds that weakly bind to a target macromolecule and will then be modified or linked to yield potent inhibitors. The specificity of these low-complexity and low-affinity molecules has rarely been discussed in the literature. To address this question, NMR spectroscopy was used to investigate the interactions of 150 fragments with five proteins: three proteins from the Bcl-2 family (Bcl-x(L), Bcl-w, and Mcl-1), human peroxiredoxin 5, for which very few ligands have been reported, and human serum albumin, which is known to bind a large number of ligands. Our results show that the fragments are rather versatile binders and able to identify binding hot spots in very different targets. Despite the different hit rates observed related to the druggability of the proteins, two scaffolds appear as preferred binders for all proteins. Low specificity was observed between homologous proteins or unrelated poorly druggable proteins, while higher specificity could be achieved with highly druggable targets.
引用
收藏
页码:5256 / 5266
页数:11
相关论文
共 66 条
[41]  
Knoops Bernard, 2007, V44, P27
[42]   Optimisation of Conoidin A, a Peroxiredoxin Inhibitor [J].
Liu, Gu ;
Botting, Catherine H. ;
Evans, Kathryn M. ;
Walton, Jeffrey A. G. ;
Xu, Guogang ;
Slawin, Alexandra M. Z. ;
Westwood, Nicholas J. .
CHEMMEDCHEM, 2010, 5 (01) :41-45
[43]   A novel approach for characterizing protein ligand complexes: Molecular basis for specificity of small-molecule Bcl-2 inhibitors [J].
Lugovskoy, AA ;
Degterev, AI ;
Fahmy, AF ;
Zhou, P ;
Gross, JD ;
Yuan, JY ;
Wagner, G .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2002, 124 (07) :1234-1240
[44]  
Mayer M, 1999, ANGEW CHEM INT EDIT, V38, P1784, DOI 10.1002/(SICI)1521-3773(19990614)38:12<1784::AID-ANIE1784>3.0.CO
[45]  
2-Q
[46]   Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1 [J].
Mohammad, Ramzi M. ;
Goustin, Anton Scott ;
Aboukameel, Amro ;
Chen, Ben ;
Banerjee, Sanjeev ;
Wang, Guoping ;
Nikolovska-Coleska, Zaneta ;
Wang, Shaomeng ;
Al-Katibl, Ayad .
CLINICAL CANCER RESEARCH, 2007, 13 (07) :2226-2235
[47]   Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis [J].
Nguyen, Mai ;
Marcellus, Richard C. ;
Roulston, Anne ;
Watson, Mark ;
Serfass, Lucile ;
Madiraju, S. R. Murthy ;
Goulet, Daniel ;
Viallet, Jean ;
Belec, Laurent ;
Billot, Xavier ;
Acoca, Stephane ;
Purisima, Enrico ;
Wiegmans, Adrian ;
Cluse, Leonie ;
Johnstone, Ricky W. ;
Beauparlant, Pierre ;
Shore, Gordon C. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (49) :19512-19517
[48]   An inhibitor of Bcl-2 family proteins induces regression of solid tumours [J].
Oltersdorf, T ;
Elmore, SW ;
Shoemaker, AR ;
Armstrong, RC ;
Augeri, DJ ;
Belli, BA ;
Bruncko, M ;
Deckwerth, TL ;
Dinges, J ;
Hajduk, PJ ;
Joseph, MK ;
Kitada, S ;
Korsmeyer, SJ ;
Kunzer, AR ;
Letai, A ;
Li, C ;
Mitten, MJ ;
Nettesheim, DG ;
Ng, S ;
Nimmer, PM ;
O'Connor, JM ;
Oleksijew, A ;
Petros, AM ;
Reed, JC ;
Shen, W ;
Tahir, SK ;
Thompson, CB ;
Tomaselli, KJ ;
Wang, BL ;
Wendt, MD ;
Zhang, HC ;
Fesik, SW ;
Rosenberg, SH .
NATURE, 2005, 435 (7042) :677-681
[49]   Is there a difference between leads and drugs? A historical perspective [J].
Oprea, TI ;
Davis, AM ;
Teague, SJ ;
Leeson, PD .
JOURNAL OF CHEMICAL INFORMATION AND COMPUTER SCIENCES, 2001, 41 (05) :1308-1315
[50]   Discovery of a potent inhibitor of the antiapoptotic protein Bcl-xL from NMR and parallel synthesis [J].
Petros, AM ;
Dinges, J ;
Augeri, DJ ;
Baumeister, SA ;
Betebenner, DA ;
Bures, MG ;
Elmore, SW ;
Hajduk, PJ ;
Joseph, MK ;
Landis, SK ;
Nettesheim, DG ;
Rosenberg, SH ;
Shen, W ;
Thomas, S ;
Wang, XL ;
Zanze, I ;
Zhang, HC ;
Fesik, SW .
JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (02) :656-663